SH: FEBRILE TOPICS OF DISCUION

Social History

Medscape's Jillian Mock's on Medical News

#MEDBIKINI: DOCTORS CALL OUT STUDY FOR SEXISM & DISCRIMINATION

The Pulse

MOST GEORGIA HOSPITALS GETTING PENALIZED FOR READMISSIONS

The Washington Post

THE AFFORDABLE CARE ACT RETURNS TO THE SUPREME COURT IN THE SHADOW OF A PANDEMIC

Lindsay Kalter, Special to AAMCNews

THE SOCIAL MEDIA DILEMMA

Mental Health Matters

Medical Student Blogger

Resources Applying Medical School

Premed Motivation Instagram

CV building for Fellow Medical Students

PERTINENT FINDINGS IN HEALTHCARE TODAY

Thorasic%20Cavity_edited.jpg

Why is this important?

In secondary applications and/or during an interview, many medical school applicants may be asked to discuss or comment on current issues and hot topics regarding the state of health care. 

Joint release by the World Health Organization, United for Global Mental Health and the World Federation for Mental Health

GLOBAL CHALLENGE FOR MOVEMENT ON MENTAL HEALTH KICKS OFF AS LACK OF INVESTMENT IN MENTAL HEALTH LEAVES MILLIONS WITHOUT ACCESS TO SERVICES

Office of Disease Prevention and Health Promotion

SOCIAL DETERMINANTS OF HEALTH

Harvard Medical School

LEARN HOW TO SLEEP AGAIN

The Pulse

MOST GEORGIA HOSPITALS GETTING PENALIZED FOR READMISSIONS

Journal of General Internal Medicine

UNDERSTANDING AFRICAN AMERICANS' VIEWS OF THE TRUSTWORTHINESS OF PHYSICIANS

NOVEL CORONAVIRUS (COVID-19) RESOURCE PAGE

COVID-19 Burdens Follow Patients After Discharge 

RACE & COVID-19: STARK DISPARITIES IN RURAL GEORGIA

JOHNS HOPKINS COVID-19 TRACKER BOARD

ASSESSING RISK FACTORS FOR SEVERE COVID-19 INFECTIONS

UNIVERSITY OF WASHINGTON IHME
COVID-19 PROJECTIONS

CC: COVID-19

Chief Complaint

FDA AUTHORIZES EMERGENCY USE FOR

ELI LILLY COVID-19 ANTIBODY TREATMENT

Vaccination

Reuters (11/9, Beasley) reports the Food and Drug Administration authorized on Monday emergency use of Eli Lilly’s “COVID-19 antibody treatment for non-hospitalized patients older than 65 or who have certain chronic medical conditions.” The FDA found that clinical trials indicated the treatment, bamlanivimab, “reduced the need for hospitalization or emergency room visits in high-risk COVID-19 patients.”

The AP (11/9, Perrone) reports the FDA “cleared the experimental drug from Eli Lilly for people 12 and older with mild or moderate COVID-19 not requiring hospitalization.” The treatment is administered once by means of an IV.

 

CNN (11/9, Fox, Christensen) reports the treatment “must be infused in a hospital or other health care setting” and “is the first monoclonal antibody to be authorized for use in treating coronavirus.”

 

NBC News (11/10, Edwards) reports that Eli Lilly “has already begun manufacturing the drug, and it said it could have as many as 1 million doses available by the end of the year.”